Introduction: The role of genetic variants in response to chemotherapy has been investigated in several studies. This study aimed to investigate genetic variants associated with response to chemotherapy in breast cancer (BC) patients. Methods: Significant variants (p < 5 × 10−8) associated with response to chemotherapy were obtained from GWA studies. Candidate variants were identified by haplotype analysis (r2 ≥ 0.9, D′≥0.9) using 1000Genome LD data. To determine the effects of the variants on gene expression, expression quantitative trait loci (eQTL) were evaluated. To compare the expression of the identified genes in tumor samples, expression levels were compared between TCGA tumor types and adjacent normal tissues. Results: Six rs3820706, rs147451859, rs4784750, rs17587029, rs16830728, and rs16972207 variants were significantly associated with response to chemotherapy in BC patients (p < 5 × 10−8). Seven novel haplotypic structures were identified to be associated with adverse response to chemotherapy in BC patients. These haplotypes formed two genetic structures associated with neutropenia, leukopenia, chemotherapy-induced cytotoxicity (GAG-TTAT), and chemotherapy-induced alopecia (CC-CAACTCCCGTTGCGG). These variants are located on PPCDC, NLRC5, STAM2, and TNFSF13B genes, and the expression of these genes significantly changed in BC tissues than normal tissues (P ≤ 0.05), also showing gene-gene correlation (P ≤ 0.05). Conclusions: These genetic variants and their associated novel haplotypic structures can predict adverse response to chemotherapy in BC patients and could potentially form BC-associated genetic panel for adverse response to chemotherapy.
GholamiMKlashamiZNEbrahimiP, et al.Metformin and long non-coding RNAs in breast cancer. J Transl Med2023; 21: 155.
4.
ChungSLowS-KZembutsuH, et al.A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res2013; 15: 1–10.
5.
RuddyKJSchaidDJPartridgeAH, et al.Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertil Steril2019; 112: 731–739. e731.
6.
FaschingPALiuDScullyS, et al.Identification of two genetic loci associated with leukopenia after chemotherapy in patients with breast cancer. Clin Cancer Res2022; 28: 3342–3355.
7.
JannotA-SEhretGPernegerT. P< 5× 10− 8 has emerged as a standard of statistical significance for genome-wide association studies. J Clin Epidemiol2015; 68: 460–465.
8.
SollisEMosakuAAbidA, et al.The NHGRI-EBI GWAS catalog: knowledgebase and deposition resource. Nucleic Acids Res2023; 51: D977–D985.
9.
SherrySTWardMSirotkinK. dbSNP—database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res1999; 9: 677–679.
10.
WardLDKellisM. Haploreg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res2012; 40: D930–D934.
11.
MuWZhangW. Molecular approaches, models, and techniques in pharmacogenomic research and development. In: Pharmacogenomics. Cambridge, MA: Academic Press, 2013, pp.273–294.
12.
CrawfordDCNickersonDA. Definition and clinical importance of haplotypes. Annu Rev Med2005; 56: 303–320.
13.
BråtenLSHaslemoTJukicMM, et al.A novel CYP2C-haplotype associated with ultrarapid metabolism of escitalopram. Clin Pharmacol Ther2021; 110: 786–793.
14.
CunninghamFAllenJEAllenJ, et al.Ensembl 2022. Nucleic Acids Res2022; 50: D988–D995.
15.
BarrettJCFryBMallerJ, et al.Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics2005; 21: 263–265.
16.
LiTFuJZengZ, et al.TIMER2. 0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res2020; 48: W509–W514.
17.
TangGChoMWangX. OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res2022; 50: D1334–D1339.
18.
SzklarczykDFranceschiniAWyderS, et al.STRING V10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res2015; 43: D447–D452.
19.
CatalanoCda Silva FilhoMIJiraskovaK, et al.Short article: influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. Eur J Gastroenterol Hepatol2018; 30: 838–842.
20.
KimHKimHFengY, et al.PRMT5 Control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med2020; 12: eaaz5683.
21.
LiangSXiangTLiuS, et al.Inhibition of NLRC5 attenuates the malignant growth and enhances the sensitivity of gastric cancer cells to 5-FU chemotherapy by blocking the carcinogenic effect of YY1. Exp Ther Med2022; 24: 1–10.
22.
KaymazBTGünelNSCeyhanM, et al.Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted “hsa-miR-2278” as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumor Biol2015; 36: 7915–7927.
23.
BidadiBLiuDKalariKR, et al.Pathway-based analysis of genome-wide association data identified SNPs in HMMR as biomarker for chemotherapy-induced neutropenia in breast cancer patients. Front Pharmacol2018; 9: 158.
